Loading chart...McKesson Corp (MCK) trades on the NYSE. The chart above shows its historical adjusted close price.

Loading chart...Here's McKesson's trailing P/E ratio computed fresh from TTM net income and daily share counts. The ratio is shown from mid-2022 onward (once four quarters of net income data became available). As of the latest data, MCK trades at a relatively modest multiple, reflecting its low-margin pharmaceutical distribution business model.

Loading chart...Here's McKesson's ROIC, calculated as NOPAT (TTM net income) over invested capital (total assets minus current liabilities minus cash). The chart shows both the quarterly TTM ROIC and the annual ROIC.

ROIC has trended in the 9–37% range over the period, with notable strength in FY23 where it peaked near 37%. More recently, quarterly TTM ROIC has settled in the mid-to-high teens, reflecting McKesson's asset-light distribution model where high working capital turnover drives solid returns on a relatively thin invested capital base.

Loading chart...Here's McKesson's quarterly TTM ROIC over the last 10 years.

A few notable periods stand out:

• FY18–FY19 trough: ROIC collapsed to near zero (~0.2–0.6%) as net income was depressed — McKesson took large goodwill impairment and restructuring charges in those years.
• FY20–FY22 recovery: ROIC climbed steadily from ~6% to ~26% as the business stabilized and profitability improved.
• FY23 peak: ROIC spiked to ~37%, driven by strong earnings in the post-pandemic pharmaceutical distribution environment.
• FY24–FY26 normalization: ROIC has settled in the mid-to-high teens, a solid level consistent with McKesson's capital-light, high-turnover distribution model.